DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Catapres-TTS-1 (Drug); Intervention 1: Catapres-TTS-3 (Drug); Intervention 1: Catapres-TTS-3 (Drug); Intervention 2: Catapres-TTS-3 (Drug); Catapres-TTS-1 (Drug); Intervention 2: Catapres-TTS-3 (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Boehringer Ingelheim

Official(s) and/or principal investigator(s):
Boehringer Ingelheim, Study Chair, Affiliation: Boehringer Ingelheim


To establish the bioequivalence and adhesion properties of transdermal clonidine prepared with OppanolŪ brands of polyisobutylene (PIB) vs. transdermal clonidine prepared with VistanexTM brands of polyisobutylene (PIB) in healthy male and female volunteers.

Clinical Details

Official title: A Randomized, Double-blind Study Designed to Assess the Bioequivalence and Adhesion Properties of Transdermal Clonidine-VistanexTM Compared to Transdermal Clonidine-OppanolŪ Following Transdermal Administration in Healthy Male and Female Volunteers

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome:

AUC0-168 (Area Under the Concentration-time Curve of Clonidine in Plasma Over the Time Interval From 0 to 168 h)

Cavg (Average of Measured Concentrations of Clonidine in Plasma on Days 5, 6, and 7)

Secondary outcome:

AUC0-inf(Area Under the Concentration-time Curve of Clonidine in Plasma Over the Time Interval From 0 to Infinity)

Cmax (Maximum Concentration of Clonidine in Plasma)


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion criteria: 1. A complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests 2. Age greater than or equal to 18 and Age less than or equal to 65 years 3. BMI greater than or equal to 18. 5 and BMI less than or equal to 32. 0 kg/m2 (Body Mass Index) 4. Signed and dated written informed consent prior to admission to the study 5. Male subjects, or females who meet any of the following criteria from at least 30 days before the first study drug administration and until 30 days after trial completion:

- Using adequate contraception, e. g. any of the following methods plus condom:

implants, injectables, combined oral contraceptives, intrauterine device (IUD)

- Sexually abstinent

- Have a vasectomised sexual partner (vasectomy at least one year prior to


- Surgically sterilised (including hysterectomy)

- Postmenopausal defined as at least one year of spontaneous amenorrhea

Exclusion criteria: 1. Any finding of the medical examination (including BP, PR and ECG) deviating from normal 2. Repeated measurement of supine systolic blood pressure outside the range of 100-140 mm Hg or diastolic blood pressure outside the range of 60-90 mm Hg or pulse less than 55 bpm 3. Any subject with orthostatic hypotension at baseline screening exam 4. Any laboratory value outside the reference range 5. Any evidence of a clinically relevant concomitant disease 6. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic (including insulin-dependent diabetes), immunological or hormonal disorders 7. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders (such as depression) or neurological disorders (such as neuropathy) 8. History of relevant orthostatic hypotension, fainting spells or blackouts 9. Chronic or relevant acute infections 10. History of relevant allergy/hypersensitivity 11. Intake of drugs with a long half-life (greater than 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial. 12. Use of drugs which might reasonably influence the results of the trial within 10 days prior to administration or during the trial 13. Participation in another trial with an investigational drug within two months prior to administration or during the trial 14. Any concomitant therapy 15. Smoker 16. History of alcohol abuse 17. History of drug abuse 18. Blood donation 19. Excessive physical activities (within one week prior to administration or during the trial) 20. Subjects should not swim during the treatment periods of the trial 21. Any condition of the skin, including eczema, psoriasis, or lymphedema, that involves the upper arm in the area that would be utilized for application of the treatments 22. Pregnancy or planning to become pregnant within two months of study completion 23. Positive pregnancy test 24. A screening ECG that displays first-degree atrioventricular block (P-R interval > 0. 20 seconds) or other conduction disturbance

Locations and Contacts

253.2486.1 Boehringer Ingelheim Investigational Site, Austin, Texas, United States
Additional Information

Starting date: March 2014
Last updated: June 19, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017